Skip to main content

Advertisement

Volume 6 Supplement 3

AIDS Vaccine 2009

P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011)

  • 779 Accesses

Background

DNA and rAd5 vaccines delivered intramuscularly have been studied in many phase I/II trials. Here, the immunogenicity of the NIAID Vaccine Research Center (VRC) DNA and rAd5 HIV-1 vaccines were evaluated after injection by intramuscular (IM), subcutaneous (SC) and intradermal (ID) routes of administration.

Methods

60 subjects were randomized to one of two schedules. Group 1 received 3 DNA vaccine injections followed by a recombinant adenoviral vector (rAd5) vaccine booster; Group 2 received rAd5 prime followed by rAd5 booster. Within each Group subjects were equally randomized to prime injections by the IM, SC or ID routes of administration and all groups received a boost with rAd5 by IM injection. Half of the subjects in each group had pre-existing Ad5 neutralizing antibody.

Results

All routes induced T cell and humoral immune responses in Ad5 naïve and pre-immune subjects. >95% of subjects made an antibody response to Env. T cell responses to Env were seen in >80% and T cell responses to Gag were seen in >50% of all study subjects. Env T cell responses were of greater magnitude than responses to Gag. The frequency and magnitude of T cell responses were not diminished in Ad5 pre-immune subjects as compared to naïve subjects in either of the ID primed groups.

Conclusion

In this exploratory study, SC delivery of DNA or rAd5 as a prime does not induce a higher frequency or magnitude of T cell immunity than IM delivery. ID delivery may provide a dose sparing effect and also deserves additional evaluation as a means to overcome pre-existing vector immunity.

Author information

Correspondence to JE Ledgerwood.

Rights and permissions

Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution 2.0 International License (https://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Reprints and Permissions

About this article

Cite this article

Ledgerwood, J., Novik, L., Enama, M. et al. P14-10. Comparable immunogenicity of VRC DNA and rAd5 HIV-1 vaccines delivered by intramuscular, subcutaneous and intradermal routes in healthy adults (VRC 011). Retrovirology 6, P198 (2009). https://doi.org/10.1186/1742-4690-6-S3-P198

Download citation

Keywords

  • Cell Response
  • Prime Injection
  • Recombinant Adenoviral Vector
  • Vaccine Injection
  • Vaccine Booster